<DOC>
	<DOC>NCT00647114</DOC>
	<brief_summary>Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.</brief_summary>
	<brief_title>A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)</brief_title>
	<detailed_description>The optional followup period for this study is 1 year after the last vaccination.</detailed_description>
	<criteria>Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment Patient must not be pregnant 3 days prior to enrollment Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent Patient has had their spleen removed or has a history of autoimmune disorders Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study Patient is known to be Human Immunodeficiency Virus (HIV)seropositive Patient has a known history of Hepatitis B or C Patient has received a vaccine for any disease or condition within one month of enrollment Patient has a primary central nervous system tumor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Cancers expressing HER-2 and/or CEA</keyword>
</DOC>